Publication

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma

Downloadable Content

Persistent URL
Last modified
  • 06/25/2025
Type of Material
Authors
    Caroline S. Jansen, Emory UniversityYujin Choi, Emory UniversitySean Evans, Emory UniversityRachel Greenwald, Emory UniversityJoseph Behnke, Emory UniversityCaitlin Hartman, Emory UniversityHaydn Thomas Kissick, Emory UniversityLara R. Harik, Emory UniversityMehmet Asim Bilen, Emory University
Language
  • English
Date
  • 2023-10-04
Publisher
  • Frontiers
Publication Version
Copyright Statement
  • © 2023 Jansen, Choi, Evans, Greenwald, Behnke, Hartman, Kissick, Harik and Bilen
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 13
Start Page
  • 1271255
Grant/Funding Information
  • The authors declare financial support was received for the research, authorship, and/or publication of this article. CJ is supported by National Cancer Institute Grant (F30CA243250) and by the Medical Scientist Training Program Grant (T32 GM008169). Research reported in this publication was supported in part by the Cancer Tissue and Pathology shared resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292.
Abstract
  • Extrarenal clear cell renal cell carcinoma (eccRCC) is a rare type of RCC that arises in areas other than the kidney. Given its rarity, consensus guidelines for optimal treatment of eccRCC have not been established, and the literature is lacking any reports of patient response to systemic therapy and any reports of administration of immunotherapy to patients with ecRCC. Here, we present the case of a patient in their 60s with eccRCC arising in the spleen. The patient underwent splenic resection and then received systemic therapy, due to disease recurrence, with a combination of immunotherapy (IO) and tyrosine kinase inhibitor targeted therapy (VEGF-TKI). The patient had an excellent and durable response to this therapeutic regimen with minimal adverse effects, completing 2 years of therapy of nivolumab and cabozantinib. At the time of this report, the disease remains stable. This case demonstrates that combination therapy with IO+VEGF-TKI represents a reasonable and well-tolerated treatment option with activity in eccRCC and reveals interesting correlative data, including nests of stem-like CD8+T-cell infiltration in tumor tissue, which provide important biological context to this patient’s exceptional therapeutic response.
Author Notes
Keywords
Research Categories
  • Health Sciences, Immunology
  • Health Sciences, Oncology

Tools

Relations

In Collection:

Items

Thumbnail Title File Description Date Uploaded Visibility Actions
file details Publication File - wch2g.pdf Primary Content 2025-06-06 Public Download